American Society of Hematology, Blood, 18(124), p. 2858-2866, 2014
DOI: 10.1182/blood-2014-03-563445
Full text: Download
Key Points Human splenic TFH expansion during ITP participates in B-cell differentiation and antiplatelet-antibody production. IL-21 and CD40 are key TFH molecules that could be promising targets in the treatment of ITP.